Targeting Th17 cells in autoimmune diseases

Trends in Pharmacological Sciences

Volumn 35, Issue 10, 2014, Pages 493-500

  Yang, Jianfei ^a   Sundrud, Mark S ^b   Skepner, Jill ^a   Yamagata, Tetsuya ^a  

^a GLAXOSMITHKLINE   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

IL 17; IL 23; ROR t autoimmune diseases

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 1BETA; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 26; RETINOID RELATED ORPHAN RECEPTOR ALPHA; RETINOID RELATED ORPHAN RECEPTOR BETA; RETINOID RELATED ORPHAN RECEPTOR GAMMA; RETINOID RELATED ORPHAN RECEPTOR GAMMA T; RETINOID RELATED ORPHAN RECEPTOR GAMMA T INVERSE AGONIST; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA3; UNCLASSIFIED DRUG; MOLECULAR LIBRARY;

AUTOIMMUNE DISEASE; BIOCHEMISTRY; CELLULAR IMMUNITY; DNA BINDING; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; HUMAN; IMMUNOPATHOGENESIS; IMMUNOREGULATION; INFLAMMATION; INTRACELLULAR SIGNALING; LIGAND BINDING; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; MOLECULAR PATHOLOGY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; STRUCTURE ACTIVITY RELATION; T LYMPHOCYTE ACTIVATION; TARGET CELL; TH17 CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; AUTOIMMUNE DISEASES; DRUG DELIVERY SYSTEM; DRUG EFFECTS; IMMUNOLOGY; MOLECULAR LIBRARY; PHARMACOLOGY;

ANIMALS; AUTOIMMUNE DISEASES; DRUG DELIVERY SYSTEMS; HUMANS; NUCLEAR RECEPTOR SUBFAMILY 1, GROUP F, MEMBER 3; SMALL MOLECULE LIBRARIES; TH17 CELLS;

EID: 84907904466     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2014.07.006     Document Type: Review

References (61)

1. C.L. Langrish IL-23 drives a pathogenic T cell population that induces autoimmune inflammation J. Exp. Med. 201 2005 233 240
2. E. Bettelli Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells Nature 441 2006 235 238
3. M. Veldhoen TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells Immunity 24 2006 179 189
4. I.I. Ivanov The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells Cell 126 2006 1121 1133
5. M. Ciofani A validated regulatory network for Th17 cell specification Cell 151 2012 289 303
6. T. Korn IL-17 and Th17 cells Annu. Rev. Immunol. 27 2009 485 517
7. P. Miossec, and J.K. Kolls Targeting IL-17 and TH17 cells in chronic inflammation Nat. Rev. Drug Discov. 11 2012 763 776
8. J.D. Milner Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome Nature 452 2008 773 776
9. C. Lock Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis Nat. Med. 8 2002 500 508
10. S. Sarkar, and D.A. Fox Targeting IL-17 and Th17 cells in rheumatoid arthritis Rheum. Dis. Clin. North Am. 36 2010 345 366
11. E. Lubberts Overexpression of IL-17 in the knee joint of collagen type II immunized mice promotes collagen arthritis and aggravates joint destruction Inflamm. Res. 51 2002 102 104
12. E. Lubberts Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion Arthritis Rheum. 50 2004 650 659
13. M.I. Koenders Interleukin-17 receptor deficiency results in impaired synovial expression of interleukin-1 and matrix metalloproteinases 3, 9, and 13 and prevents cartilage destruction during chronic reactivated streptococcal cell wall-induced arthritis Arthritis Rheum. 52 2005 3239 3247
14. K.M. Robinson Clinical consequences of targeting IL-17 and TH17 in autoimmune and allergic disorders Curr. Allergy Asthma Rep. 13 2013 587 595
15. K.A. Papp Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study Br. J. Dermatol. 168 2013 412 421
16. K.A. Papp Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis N. Engl. J. Med. 366 2012 1181 1189
17. M.C. Genovese Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study Ann. Rheum. Dis. 72 2013 863 869
18. D.A. Martin A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis Arthritis Res. Ther. 15 2013 R164
19. W. Hueber Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial Gut 61 2012 1693 1700
20. S.R. Targan A randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and efficacy of AMG 827 in subjects with moderate to severe Crohn's disease Gastroenterology 143 2012 e26
21. B.M. Segal Th17 cells in autoimmune demyelinating disease Semin. Immunopathol. 32 2010 71 77
22. W. O'Connor Jr A protective function for interleukin 17A in T cell-mediated intestinal inflammation Nat. Immunol. 10 2009 603 609
23. A.M. Jetten Retinoid-related orphan receptors (RORs): critical roles in development, immunity, circadian rhythm, and cellular metabolism Nucl. Recept. Signal. 7 2009 e003
24. N. Manel The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat Nat. Immunol. 9 2008 641 649
25. M.J. McGeachy TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology Nat. Immunol. 8 2007 1390 1397
26. Y. Lee Induction and molecular signature of pathogenic T(H)17 cells Nat. Immunol. 13 2012 991 999
27. L. Codarri RORγt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation Nat. Immunol. 12 2011 560 567
28. M. El-Behi The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF Nat. Immunol. 12 2011 568 575
29. L.A. Solt, and T.P. Burris Action of RORs and their ligands in (patho)physiology Trends Endocrinol. Metab. 23 2012 619 627
30. J.R. Huh Digoxin and its derivatives suppress TH17 cell differentiation by antagonizing RORγt activity Nature 472 2011 486 490
31. N. Kumar The benzenesulfoamide T0901317 [N-(2,2,2-trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethy l]phenyl]-benzenesulfonamide] is a novel retinoic acid receptor-related orphan receptor-alpha/gamma inverse agonist Mol. Pharmacol. 77 2010 228 236
32. L.A. Solt Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand Nature 472 2011 491 494
33. T. Xu Ursolic acid suppresses interleukin-17 (IL-17) production by selectively antagonizing the function of RORgamma t protein J. Biol. Chem. 286 2011 22707 22710
34. J. Skepner Pharmacologic inhibition of RORγt regulates Th17 signature gene expression and suppresses cutaneous inflammation in vivo J. Immunol. 192 2014 2564 2575
35. R. Cascao Effective treatment of rat adjuvant-induced arthritis by celastrol Autoimmun. Rev. 11 2012 856 862
36. S. Fujita-Sato Structural basis of digoxin that antagonizes RORgamma t receptor activity and suppresses Th17 cell differentiation and interleukin (IL)-17 production J. Biol. Chem. 286 2011 31409 31417
37. S. Xiao Chemical inhibition of the RORγt-dependent transcriptional network in T helper 17 cells Immunity 40 2014 477 489
38. H17 cells and stimulates T regulatory cells ACS Chem. Biol. 7 2012 1515 1519
39. N. Kumar Identification of SR2211: a potent synthetic RORγ-selective modulator ACS Chem. Biol. 7 2012 672 677
40. M.R. Chang Pharmacologic repression of retinoic acid receptor-related orphan nuclear receptor gamma is therapeutic in the collagen-induced arthritis experimental model Arthritis Rheumatol. 66 2014 579 588
41. B.P. Fauber, and S. Magnuson Modulators of the nuclear receptor retinoic acid receptor-related orphan receptor-γ (RORγ or RORc) J. Med. Chem. 57 2014 10.1021/jm401901d
42. M.J. McGeachy The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo Nat. Immunol. 10 2009 314 324
43. D.J. Cua Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain Nature 421 2003 744 748
44. M. Cargill A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes Am. J. Hum. Genet. 80 2007 273 290
45. P. Rahman Association of interleukin 23 receptor variants with psoriatic arthritis J. Rheumatol. 36 2009 137 140
46. R.H. Duerr A genome-wide association study identifies IL23R as an inflammatory bowel disease gene Science 314 2006 1461 1463
47. P. Rahman Association of interleukin-23 receptor variants with ankylosing spondylitis Arthritis Rheum. 58 2008 1020 1025
48. M. Oosting Role of interleukin-23 (IL-23) receptor signaling for IL-17 responses in human Lyme disease Infect. Immun. 79 2011 4681 4687
49. P.R. Burton Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants Nat. Genet. 39 2007 1329 1337
50. S.R. Wen Increased levels of IL-23 and osteopontin in serum and cerebrospinal fluid of multiple sclerosis patients J. Neuroimmunol. 244 2012 94 96
51. H. Puwipirom Increased interleukin-23 receptor(+) T cells in peripheral blood mononuclear cells of patients with systemic lupus erythematosus Arthritis Res. Ther. 12 2010 R215
52. A.K. Huber Interleukin (IL)-23 receptor is a major susceptibility gene for Graves' ophthalmopathy: the IL-23/T-helper 17 axis extends to thyroid autoimmunity J. Clin. Endocrinol. Metab. 93 2008 1077 1081
53. N. Figueroa-Vega Increased circulating pro-inflammatory cytokines and Th17 lymphocytes in Hashimoto's thyroiditis J. Clin. Endocrinol. Metab. 95 2010 953 962
54. C.L. Leonardi Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) Lancet 371 2008 1665 1674
55. A.L. Croxford IL-23: one cytokine in control of autoimmunity Eur. J. Immunol. 42 2012 2263 2273
56. K.A. Papp Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) Lancet 371 2008 1675 1684
57. I.B. McInnes Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial Lancet 382 2013 780 789
58. P. Traczewski, and L. Rudnicka Briakinumab for the treatment of plaque psoriasis BioDrugs 26 2012 9 20
59. P.J. Mannon Anti-interleukin-12 antibody for active Crohn's disease N. Engl. J. Med. 351 2004 2069 2079
60. W.J. Sandborn A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease Gastroenterology 135 2008 1130 1141
61. W.J. Sandborn Ustekinumab induction and maintenance therapy in refractory Crohn's disease N. Engl. J. Med. 367 2012 1519 1528